The delivery of medication from the AEROECLIPSE* II BAN* to the lungs was not affected by the incorporation of the Aerobika* OPEP device. Aerosol deposition within the lung was unaltered by the addition of the OPEP device as evidenced by the near identical percentage of the dose being deposited in both the peripheral and central airways.
BAN+OPEP therapy could offer the clinician the opportunity for combined treatment thereby reducing the time needed for the patient to take both nebulizer and OPEP treatments separately.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
A systematic review of nebulizer use highlighted a few different potential mechanisms for fugitive emissions. Differences in nebulizer design had an impact in the amount and type of fugitive emissions emitted.
Through the choice of an appropriate nebulizer, the natural risk can be greatly reduced, and through selection of appropriate mitigation strategies, the risk can be almost eliminated.
Medications to manage care of bronchiectasis and NTM patients are often delivered via a nebulizer. This study compares a number of different OPEP/Nebulizer combinations using salbutamol as the modelled medication.
Inhaled tobramycin is recommended for use in cystic fibrosis patients for treatment of Pseudomonas aeruginosa infection. This in vitro study looked at antibiotic delivery using a BA nebulizer/compressor system and two BE nebulizer/compressor systems.
Medications to manage care of bronchiectasis and NTM patients are often delivered via a nebulizer. This study compares a number of different OPEP/Nebulizer combinations using salbutamol as the modelled medication.
Various improvements have been made to the basic jet nebulizer design with the intent of delivering more medication to the distal airways while still providing aerosol within the respirable range of 3 – 5 μm.
As a medical device manufacturer, we are committed to minimizing any disruption to the supply of our products to our customers globally, during this unprecedented time with the outbreak of COVID-19.
